Inhibitors of the three novel IRGs (INHBA, HELLS, and HDAC4) might activate immune cells in ACC immune microenvironment and play a synergistic role in combination therapy with immunotherapy for ACC in the future. This evidence concerns the gene HDAC4 and adrenal cortex carcinoma.